baculovirusinsect
cell
express
system
well
known
tool
product
complex
protein
technolog
also
use
commerci
manufactur
variou
veterinari
human
vaccin
review
paper
provid
overview
technolog
appli
produc
multitud
vaccin
candid
key
advantag
recombin
protein
manufactur
platform
univers
plug
play
process
may
use
produc
broad
rang
proteinbas
prophylact
therapeut
vaccin
human
veterinari
use
offer
potenti
low
manufactur
cost
larg
scale
mammalian
cell
cultur
facil
previous
establish
manufactur
monoclon
antibodi
becom
obsolet
due
yield
improv
could
deploy
manufactur
vaccin
altern
manufactur
capac
could
establish
geograph
region
vaccin
product
capabl
depend
health
care
prioriti
differ
vaccin
could
manufactur
maintain
abil
rapidli
convert
produc
pandem
influenza
vaccin
need
aris
major
world
health
organ
recommend
vaccin
routin
immun
deriv
kill
inactiv
liveattenu
infect
agent
overview
twenti
recommend
vaccin
etiolog
agent
diseas
impact
method
manufactur
provid
tabl
nine
liveattenu
vaccin
lav
histor
creat
passag
pathogen
organ
cultur
cell
vaccin
almost
complet
devoid
pathogen
howev
empir
attenu
may
unreli
pose
potenti
safeti
issu
ie
revers
pathogen
genotyp
tel
fax
email
address
manoncox
proteinsciencescom
advanc
molecular
virolog
provid
new
way
control
viral
replic
virul
may
lead
new
gener
safer
wide
applic
lav
vaccin
manufactur
lav
requir
growth
attenu
strain
larg
quantiti
thirteen
vaccin
inactiv
deriv
pathogen
polysaccharid
vaccin
allevi
potenti
safeti
concern
pose
lav
obtain
cultiv
often
highli
pathogen
organ
larg
quantiti
pose
potenti
exposur
risk
worker
environ
two
twenti
recommend
vaccin
recombin
protein
vaccin
first
avail
recombin
subunit
hepat
b
vaccin
engerixb
gsk
recombivax
hb
merck
licens
gradual
replac
plasmaderiv
hepat
b
vaccin
vaccin
purifi
surfac
antigen
hbsag
viru
obtain
cultur
genet
engin
saccharomyc
cerevisia
poliomyel
acut
communic
diseas
human
vaccin
led
polio
control
sinc
polio
erad
inactiv
liveattenu
oral
vaccin
deriv
three
serotyp
dtp
diphtheria
tetanu
pertussi
cerevisia
cell
antigen
purifi
sever
physicochem
step
formul
suspens
antigen
adsorb
aluminum
hydroxid
took
nearli
twenti
year
next
recombin
vaccin
gardasil
merck
cervarix
gsk
licens
human
papilloma
viru
vaccin
consist
purifi
structur
protein
major
capsid
produc
either
cerevisia
cell
gardasil
baculoviru
express
vector
system
cervarix
advantag
recombin
vaccin
contain
pathogen
genet
materi
therefor
caus
diseas
addit
recombin
vaccin
depend
cultiv
pathogen
organ
offer
potenti
util
flexibl
multipurpos
manufactur
facil
howev
inactiv
recombin
vaccin
gener
less
efficaci
lav
counterpart
therefor
often
requir
use
adjuv
baculovirusinsect
cell
express
system
often
refer
bev
well
known
tool
produc
complex
protein
provid
rapid
access
biolog
activ
protein
protein
product
platform
extens
explor
product
viral
parasit
antigen
recent
vaccin
commerci
demonstr
potenti
commerci
manufactur
technolog
baculovirus
insect
pathogen
caus
fatal
diseas
lepidopteran
dipteran
hymenopteran
larva
result
use
biocontrol
agent
insect
pest
agricultur
forestri
character
narrow
host
rang
inabl
replic
vertebr
includ
man
baculovirus
commonli
found
green
veget
therefor
part
daili
diet
healthi
individu
exampl
typic
serv
coleslaw
contain
million
polyhedra
contain
multipl
baculoviru
virion
baculoviru
particl
virion
contain
larg
doublestrand
dna
genom
averag
depend
viru
speci
kb
pair
size
easili
character
genet
manipul
propag
cell
line
deriv
ao
fall
armyworm
spodoptera
frugiperda
sf
cabbag
looper
trichoplusia
ni
ni
grow
well
suspens
cultur
summer
smith
demonstr
polyhedrin
major
capsul
protein
essenti
propag
viru
cell
cultur
open
read
frame
could
exchang
sequenc
encod
protein
medic
import
mark
begin
bev
express
era
sinc
thousand
protein
produc
use
polyhedrin
promot
later
promot
drive
express
insect
cell
capabl
perform
mani
posttransl
modif
glycosyl
disulfid
bond
format
phosphoryl
requir
biolog
activ
mani
complex
protein
protein
interest
usual
produc
control
polyhedrin
promot
one
strongest
promot
known
natur
potenti
bev
platform
enorm
transient
natur
make
attract
plug
play
protein
product
system
singl
well
character
cell
line
use
product
protein
therebi
elimin
timeconsum
process
prepar
qualifi
secur
regulatori
approv
new
cell
line
new
protein
develop
univers
protein
purif
process
one
begin
imagin
singl
multiproduct
product
facil
could
establish
produc
multitud
vaccin
combat
broad
rang
diseas
potenti
illustr
commerci
avail
vaccin
advanc
clinic
develop
applic
produc
varieti
recommend
vaccin
vaccin
unmet
medic
need
manufactur
recombin
vaccin
offer
opportun
produc
broad
rang
vaccin
multipurpos
product
facil
lower
cost
bev
technolog
establish
versatil
robust
vaccin
manufactur
platform
five
commerci
avail
vaccin
four
differ
indic
produc
insect
cell
summar
tabl
first
commerci
avail
veterinari
vaccin
produc
insect
cell
classic
swine
fever
viru
csfv
vaccin
vaccin
base
antigen
receiv
european
market
author
csf
anim
health
list
notifi
diseas
one
import
contagi
diseas
pig
classic
clinic
form
acut
hemorrhag
diseas
accompani
high
fever
depress
anorexia
conjunct
morbid
mortal
high
may
reach
took
nearli
seven
year
second
veterinari
vaccin
receiv
market
author
tabl
contain
g
protein
g
protein
selfassembl
form
viru
like
particl
vlp
resembl
hpv
type
protein
produc
ni
cell
purifi
adsorb
onto
proprietari
aso
adjuv
system
contain
g
aluminum
hydroxid
g
monophosphoryl
lipid
second
product
human
use
licens
fda
proveng
autolog
prostatecanc
therapi
product
antigen
prostat
surfac
antigen
psa
produc
frugiperda
cell
vaccin
human
clinic
develop
summar
tabl
product
subject
recent
review
mena
kamen
recombin
influenza
vaccin
flublok
base
hemagglutinin
ha
surfac
antigen
like
next
bev
deriv
vaccin
receiv
market
author
statu
recombin
vaccin
develop
use
differ
protect
antigen
target
thirteen
viral
vaccin
recommend
summar
tabl
influenza
vaccin
candid
preclin
develop
high
develop
cost
new
medicin
product
often
prohibit
develop
product
ultim
could
produc
much
lower
cost
current
vaccin
exampl
develop
flublok
taken
nearli
twenti
year
estim
develop
cost
approach
million
even
though
scientif
challeng
program
limit
hemagglutinin
ha
establish
protect
antigen
influenza
diseas
quit
well
understood
make
clinic
develop
rather
straightforward
therefor
surpris
progress
recombin
vaccin
develop
made
vaccin
high
price
charg
hpv
vaccin
public
support
enabl
develop
recombin
vaccin
exampl
center
diseas
control
cdc
price
one
dose
cervarix
vaccin
versu
price
combin
mmr
measl
mump
rubella
vaccin
dose
two
exampl
suitabl
candid
develop
use
insect
cell
product
platform
rabi
japanes
enceph
discuss
greater
detail
rabi
form
enceph
caus
death
year
would
excel
diseas
candid
vaccin
develop
current
vaccin
cost
high
typic
exceed
cours
rabi
immun
globulin
five
dose
vaccin
given
four
week
period
thu
urgent
need
cheaper
rabi
vaccin
rabi
viru
rabv
belong
genu
lyssaviru
famili
rhabdovirida
rna
rabv
encod
five
protein
includ
g
glycoprotein
carri
main
antigen
site
human
infect
usual
occur
follow
transderm
bite
scratch
infect
anim
alreadi
fu
et
al
show
protein
g
produc
insect
cell
effect
vaccin
racoon
rabi
unfortun
surprisingli
much
addit
progress
made
sinc
japanes
enceph
je
also
excel
candid
subunit
vaccin
develop
je
mosquitoborn
diseas
import
form
viral
enceph
asia
je
viru
caus
least
case
clinic
diseas
year
mostli
among
children
age
year
result
death
case
longterm
neuropsychiatr
sequela
je
viru
member
genu
flaviviru
flavivirida
famili
compris
virus
includ
dengu
yellow
fever
west
nile
virus
virion
consist
singlestrand
rna
molecul
enclos
core
membran
envelop
e
protein
e
protein
contain
antigen
determin
respons
hemagglutin
neutral
induc
protect
immun
host
therefor
e
antigen
promis
target
vaccin
develop
antigen
produc
insect
cell
form
particul
biochem
biophys
equival
authent
antigen
obtain
infect
mosquito
abl
induc
neutral
antibodi
titer
mice
vaccin
desper
need
broad
rang
diseas
includ
malaria
hiv
emerg
highli
pathogen
arbovirus
cours
neglect
diseas
caus
variou
protozoa
recent
estim
malaria
suggest
sever
hundr
million
clinic
case
death
annual
mani
malaria
vaccin
candid
produc
use
insect
cell
product
system
unfortun
insuffici
progress
made
vaccin
candid
remain
stuck
preclin
develop
lack
progress
caus
part
diseas
mechan
well
enough
understood
complex
conduct
clinic
studi
endem
region
absenc
econom
incent
hiv
anoth
diseas
even
though
human
clinic
trial
variant
produc
insect
cell
microgenesi
alreadi
conduct
earli
nineti
much
progress
made
sinc
initi
caus
lack
understand
combat
viru
enter
bodi
later
avail
rel
effect
antivir
drug
opportun
use
bev
develop
arthropodborn
arboviru
vaccin
chikungunya
dengu
west
nile
rif
valley
fever
blue
tongu
virus
recent
review
elsewher
excel
review
discuss
threat
emerg
vectorborn
viral
diseas
result
increas
global
interact
combin
climat
chang
increas
popul
densiti
describ
vaccin
alreadi
commerci
avail
develop
review
van
oer
also
describ
potenti
bev
develop
vaccin
diseas
caus
protozoa
howev
protect
antigen
hookworm
diseas
schistosomiasi
also
known
bilharziasi
yet
well
understood
may
vaccin
diseas
becom
avail
manufactur
cost
import
vaccin
especi
emerg
diseas
primarili
endem
develop
world
usual
carri
highprofit
margin
capit
invest
requir
establish
product
capac
product
yield
key
driver
cost
good
exampl
doubl
capit
invest
cost
million
increas
cost
per
dose
doubl
yield
output
per
l
reduc
cost
per
dose
bev
may
attract
choic
manufactur
capac
exist
therebi
reduc
invest
absolut
minimum
recombin
protein
yield
high
multipl
opportun
improv
exist
describ
process
step
produc
recombin
protein
insect
cell
shown
fig
describ
earlier
protect
antigen
insert
baculoviru
gener
recombin
viru
plug
play
amplifi
insect
cell
gener
work
viru
bank
wvb
insect
cell
grown
bioreactor
infect
wvb
expand
insect
cell
scale
approxim
smaller
protein
product
bioreactor
cell
separ
media
use
centrifug
depend
product
produc
either
cell
past
supernat
process
protein
interest
solubil
applic
process
use
depth
filtrat
captur
use
column
chromatographi
purifi
use
addit
chromatographi
potenti
contamin
remov
requir
use
membran
filtrat
technolog
final
product
brought
final
buffer
composit
use
ultrafiltr
process
step
indic
ital
routin
use
monoclon
antibodi
product
mani
product
facil
becom
obsolet
result
yield
improv
achiev
mammalian
cell
cultur
manufactur
process
facil
could
use
insect
cell
base
product
process
technolog
also
particularli
suitabl
address
health
care
emerg
current
pose
pandem
influenza
manufactur
technolog
readili
econom
transfer
countri
estim
suffici
monoval
bulk
protein
capac
exist
worldwid
produc
approxim
million
dose
contain
g
rha
cycl
report
fedson
dunnil
million
dose
vaccin
contain
gdose
could
produc
within
one
month
global
bioreactor
capac
alloc
rha
vaccin
product
order
address
potenti
threat
pandem
taken
major
initi
increas
global
equit
access
influenza
vaccin
technolog
transfer
eleven
vaccin
manufactur
base
brazil
egypt
india
indonesia
iran
mexico
republ
korea
romania
serbia
thailand
vietnam
select
particip
program
major
effort
base
produc
inactiv
influenza
vaccin
embryon
chicken
egg
tremend
progress
made
howev
becom
appar
difficult
maintain
product
capac
pandem
absenc
regular
buyer
vaccin
henc
sustain
vaccin
suppli
guarante
unless
econom
motiv
maintain
capac
bev
product
facil
could
rapidli
chang
produc
pandem
influenza
vaccin
need
make
vaccin
need
absenc
pandem
threat
high
potenti
lower
cost
good
recombin
protein
product
yield
improv
opportun
includ
explor
altern
baculoviru
promot
chimaer
promot
modifi
baculovirus
cathepsinchitinaseneg
acmnpv
bacmid
develop
fedbatch
ferment
process
yield
improv
also
frequent
report
result
improv
cell
cultur
media
addit
plant
hydrolys
growth
product
enhanc
factor
control
proteolysi
review
ikonom
et
al
offer
promis
yield
improv
specif
ad
plant
hydrolys
hypep
insect
cell
cultur
result
doubl
express
report
gene
also
simpl
chang
ph
may
offer
great
benefit
final
shown
viral
host
modif
improv
cell
surviv
product
heterolog
protein
modif
host
insect
cell
line
exampl
includ
antiapoptot
gene
may
limit
cytopath
effect
baculoviru
may
result
enhanc
express
recent
report
sindbi
viru
mammalian
cell
line
coexpress
chaperon
may
also
promis
prospect
effici
product
recombin
secretori
protein
insect
cell
recent
report
instanc
kato
et
al
approv
variou
vaccin
includ
recent
cervarix
gsk
human
papilloma
viru
vaccin
produc
use
insect
cell
clearli
demonstr
bev
product
technolog
matur
commerci
manufactur
technolog
variou
product
made
insect
cell
approv
commerci
use
product
develop
uncertainti
greatli
reduc
larg
number
product
develop
therefor
expect
see
acceler
product
manufactur
insect
cell
near
futur
may
also
see
followon
product
gener
develop
enter
field
within
next
year
review
overview
provid
broad
applic
technolog
alreadi
avail
vaccin
mani
unmet
medic
need
plug
play
natur
technolog
provid
potenti
sustain
vaccin
suppli
develop
world
counti
product
facil
use
produc
vaccin
relev
need
particular
countri
product
cost
vaccin
low
current
avail
recombin
vaccin
character
high
cost
bev
technolog
offer
intrins
possibl
afford
vaccin
ha
product
level
obtain
use
bev
technolog
greater
obtain
grow
influenza
virus
mdck
cell
result
substanti
lower
cost
good
influenza
vaccin
furthermor
mani
opportun
process
improv
enabl
even
greater
reduct
product
cost
includ
molecular
biolog
approach
media
develop
altern
cell
cultur
strategi
shown
previous
improv
antibodi
product
mammalian
cell
could
obtain
implement
continu
fedbatch
process
worldwid
overcapac
mammalian
protein
manufactur
reduc
capit
invest
requir
bev
product
absolut
minimum
sharp
contrast
substanti
capit
invest
biolog
contain
facil
requir
influenza
virus
cultiv
cell
line
exemplifi
novarti
invest
estim
million
bev
technolog
also
like
offer
power
first
line
defens
combat
emerg
new
virus
due
increas
contact
human
wildlif
vaccin
zoonot
diseas
caus
exampl
human
immunodefici
viru
hiv
west
nile
viru
chikungunya
viru
marburg
viru
ebola
viru
desper
need
bev
technolog
provid
great
opportun
develop
vaccin
surfac
antigen
offer
promis
fast
approach
exemplifi
viru
neutral
antibodi
induc
spike
protein
antigen
deriv
sar
coronaviru
howev
import
acknowledg
may
easi
even
feasibl
identifi
antigen
offer
protect
demonstr
failur
develop
effect
vaccin
hiv
past
two
decad
insect
cell
product
technolog
could
deploy
develop
inexpens
safe
efficaci
vaccin
list
tabl
note
subunit
vaccin
alway
gener
potent
immun
respons
need
protect
certain
pathogen
especi
diseas
like
polio
rotaviru
measl
rubella
yellow
fever
mump
safe
effect
afford
lav
candid
avail
may
use
pursu
develop
recombin
vaccin
time
would
also
use
explor
safe
effect
adjuv
stimul
immun
respons
insect
cellderiv
recombin
protein
also
use
vaccin
cancer
thu
commerci
scaleup
manufactur
technolog
beyond
viral
vaccin
may
broad
implic
diseas
control
treatment
gener
